Melatonin: A Comprehensive Review of its Synthesis, Regulation, Pleiotropic Effects, and Therapeutic Potential Across the Lifespan

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Melatonin (N-acetyl-5-methoxytryptamine) is a ubiquitous indoleamine hormone primarily synthesized and secreted by the pineal gland. While its primary role in regulating circadian rhythms and sleep-wake cycles is well-established, accumulating evidence underscores its pleiotropic effects extending far beyond sleep modulation. This review provides a comprehensive overview of melatonin’s synthesis, regulatory mechanisms, and diverse physiological roles throughout the lifespan. We explore the intricate interplay between light exposure, aging, and genetic factors in modulating melatonin production. Furthermore, we delve into the antioxidant, anti-inflammatory, immunomodulatory, and oncostatic properties of melatonin, highlighting its potential therapeutic applications in various conditions, including sleep disorders, neurodegenerative diseases, metabolic syndrome, and cancer. Finally, we critically evaluate the current evidence regarding the safety and efficacy of melatonin supplementation and discuss future research directions to fully unlock the therapeutic potential of this multifaceted molecule.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Melatonin, a hormone structurally derived from tryptophan, was first isolated from bovine pineal glands by Lerner et al. in 1958 [1]. Initially recognized for its skin-lightening properties in amphibians, it was soon appreciated that melatonin plays a crucial role in the regulation of circadian rhythms and sleep. While the pineal gland remains the primary source of circulating melatonin, it is now understood that melatonin is also synthesized in various extra-pineal tissues, including the retina, gastrointestinal tract, bone marrow, and lymphocytes [2]. These locally produced melatonin pools are thought to exert autocrine and paracrine effects, contributing to a diverse array of physiological processes. This review aims to provide a detailed examination of melatonin’s biosynthesis, regulation, and multifaceted functions, with a focus on its therapeutic potential across different stages of life.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Biosynthesis and Metabolism of Melatonin

The synthesis of melatonin is a multi-step enzymatic process that begins with the uptake of tryptophan into pinealocytes. Tryptophan is then hydroxylated to 5-hydroxytryptophan by tryptophan hydroxylase (TPH). Aromatic L-amino acid decarboxylase (AADC) converts 5-hydroxytryptophan to serotonin. Serotonin is then acetylated by arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin synthesis, forming N-acetylserotonin. Finally, N-acetylserotonin is methylated by acetylserotonin O-methyltransferase (ASMT), also known as hydroxyindole-O-methyltransferase (HIOMT), to produce melatonin [3].

AANAT activity exhibits a marked circadian rhythm, driven by the suprachiasmatic nucleus (SCN), the master circadian pacemaker located in the hypothalamus. In mammals, SCN regulates melatonin synthesis via multisynaptic pathway involving sympathetic preganglionic neurons in the spinal cord, superior cervical ganglion (SCG), and postganglionic fibers terminating in the pineal gland. During darkness, sympathetic nerve activity increases, leading to norepinephrine release in the pineal gland. Norepinephrine then activates α1- and β-adrenergic receptors, increasing intracellular cyclic AMP (cAMP) levels and subsequently activating protein kinase A (PKA). PKA phosphorylates and activates AANAT, resulting in increased melatonin production [4].

Melatonin is rapidly metabolized, primarily in the liver, via cytochrome P450 enzymes (CYP1A1, CYP1A2, and CYP2C19) to 6-hydroxymelatonin. This metabolite is then conjugated with sulfate or glucuronide, rendering it water-soluble for excretion in the urine [5]. The short half-life of melatonin in circulation (approximately 20-50 minutes) necessitates continuous synthesis for sustained physiological effects. Furthermore, inter-individual variability in CYP enzyme activity can significantly influence melatonin clearance rates and circulating levels.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Regulation of Melatonin Production

3.1 Light Exposure

Light is the most potent environmental regulator of melatonin synthesis. Retinal ganglion cells containing melanopsin, a photopigment sensitive to blue light, project directly to the SCN via the retinohypothalamic tract (RHT). Light exposure during the biological night suppresses melatonin production by inhibiting sympathetic nerve activity to the pineal gland. This acute suppression of melatonin is crucial for maintaining proper circadian alignment with the external environment [6]. The spectral sensitivity of melanopsin peaks around 480 nm, making blue light particularly effective at suppressing melatonin. Therefore, exposure to electronic devices emitting blue light, especially in the evening, can disrupt melatonin production and negatively impact sleep.

3.2 Aging

Melatonin production declines significantly with age. This age-related decline is attributed to several factors, including decreased pineal gland volume, reduced AANAT activity, and diminished responsiveness to sympathetic stimulation [7]. The reduction in melatonin levels contributes to age-related sleep disturbances, such as decreased sleep duration, increased sleep fragmentation, and reduced sleep efficiency. Furthermore, the loss of melatonin’s antioxidant and immunomodulatory properties may contribute to the increased susceptibility to age-related diseases [8].

3.3 Genetic Factors

Genetic variations in genes involved in melatonin synthesis and signaling can influence melatonin levels and circadian rhythms. Polymorphisms in MTNR1A and MTNR1B, the genes encoding melatonin receptors MT1 and MT2, respectively, have been associated with altered sleep patterns, increased risk of type 2 diabetes, and other metabolic disorders [9]. Additionally, variations in genes involved in circadian clock function, such as PER3 and CLOCK, can indirectly affect melatonin production and sleep timing. While the precise contribution of genetic factors to melatonin regulation is still under investigation, it is clear that individual genetic makeup plays a significant role in determining melatonin profiles and susceptibility to circadian rhythm disorders.

3.4 Other Factors

Several other factors can influence melatonin production, including:
* Diet: While tryptophan is the precursor to melatonin, dietary tryptophan supplementation has not consistently been shown to significantly increase melatonin levels. However, diets rich in antioxidants and certain micronutrients may indirectly support pineal gland function [10].
* Pharmacological Agents: Certain medications, such as beta-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), and benzodiazepines, can interfere with melatonin synthesis or receptor signaling [11].
* Stress: Chronic stress can disrupt the hypothalamic-pituitary-adrenal (HPA) axis and alter circadian rhythms, potentially impacting melatonin production [12].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Melatonin Receptors and Signaling Pathways

Melatonin exerts its effects by binding to two high-affinity G protein-coupled receptors, MT1 and MT2. These receptors are widely distributed throughout the body, including the brain, cardiovascular system, immune system, and gastrointestinal tract. MT1 receptors are primarily involved in inhibiting neuronal firing and regulating sleep-wake cycles, while MT2 receptors are implicated in circadian phase shifting and reproductive function [13].

Activation of MT1 and MT2 receptors initiates a cascade of intracellular signaling events, including:
* Inhibition of adenylyl cyclase: Both MT1 and MT2 receptors can inhibit adenylyl cyclase, leading to a decrease in cAMP levels and subsequent inactivation of protein kinase A (PKA).
* Activation of phospholipase C (PLC): MT1 receptors can activate PLC, leading to an increase in intracellular calcium levels.
* Modulation of potassium channels: Both MT1 and MT2 receptors can modulate the activity of potassium channels, influencing neuronal excitability.
* Activation of mitogen-activated protein kinase (MAPK) pathways: Melatonin signaling can activate MAPK pathways, including ERK1/2, JNK, and p38 MAPK, which are involved in cell growth, differentiation, and survival [14].

In addition to receptor-mediated signaling, melatonin can also exert direct antioxidant effects by scavenging free radicals. This non-receptor-mediated activity contributes to melatonin’s protective effects against oxidative stress and cellular damage.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Pleiotropic Effects of Melatonin

5.1 Chronobiotic Effects

Melatonin’s primary function is to regulate circadian rhythms and sleep-wake cycles. By binding to MT1 and MT2 receptors in the SCN, melatonin synchronizes the internal biological clock with the external environment. Melatonin administration can be used to treat circadian rhythm disorders, such as jet lag, shift work disorder, and delayed sleep phase syndrome [15].

5.2 Antioxidant Effects

Melatonin is a potent antioxidant that can protect against oxidative stress by directly scavenging free radicals, including hydroxyl radicals, superoxide anions, and peroxynitrite. Furthermore, melatonin can stimulate the expression of antioxidant enzymes, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase [16]. These antioxidant properties contribute to melatonin’s protective effects against age-related diseases, neurodegenerative disorders, and cancer.

5.3 Anti-inflammatory Effects

Melatonin possesses anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6. It also suppresses the activation of the NF-κB signaling pathway, a key regulator of inflammation [17]. These anti-inflammatory effects contribute to melatonin’s therapeutic potential in inflammatory diseases, such as arthritis, inflammatory bowel disease, and sepsis.

5.4 Immunomodulatory Effects

Melatonin can modulate immune function by influencing the activity of various immune cells, including lymphocytes, macrophages, and natural killer (NK) cells. It can enhance the production of antibodies, stimulate the proliferation of lymphocytes, and increase the cytotoxicity of NK cells [18]. These immunomodulatory effects contribute to melatonin’s ability to enhance immune responses to infections and cancer.

5.5 Oncostatic Effects

Melatonin has been shown to exhibit oncostatic effects in various cancer cell lines and animal models. It can inhibit cancer cell proliferation, induce apoptosis, suppress angiogenesis, and prevent metastasis. The mechanisms underlying these oncostatic effects are complex and involve multiple signaling pathways, including:
* Inhibition of telomerase activity: Melatonin can inhibit telomerase, an enzyme that maintains telomere length and is essential for cancer cell survival [19].
* Modulation of cell cycle regulation: Melatonin can arrest the cell cycle in G1 or G2/M phase, preventing cancer cell proliferation [20].
* Regulation of apoptosis-related proteins: Melatonin can increase the expression of pro-apoptotic proteins, such as Bax and Bak, and decrease the expression of anti-apoptotic proteins, such as Bcl-2 and Bcl-xL [21].

While the evidence for melatonin’s oncostatic effects is promising, further clinical trials are needed to determine its efficacy in cancer treatment.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Therapeutic Applications of Melatonin

6.1 Sleep Disorders

Melatonin supplementation is widely used to treat various sleep disorders, including:
* Insomnia: Melatonin can improve sleep onset latency, sleep duration, and sleep quality in individuals with insomnia, particularly in those with delayed sleep phase syndrome or low endogenous melatonin levels [22].
* Jet lag: Melatonin can help to resynchronize the circadian clock after traveling across multiple time zones, reducing the symptoms of jet lag [23].
* Shift work disorder: Melatonin can improve sleep and alertness in shift workers who experience disrupted sleep patterns due to their work schedules [24].

6.2 Neurodegenerative Diseases

Melatonin’s antioxidant and anti-inflammatory properties make it a potential therapeutic agent for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. Studies have shown that melatonin can protect against neuronal damage, reduce oxidative stress, and improve cognitive function in animal models of these diseases [25]. However, clinical trials in humans have yielded mixed results, and further research is needed to determine the efficacy of melatonin in treating neurodegenerative diseases.

6.3 Metabolic Syndrome

Melatonin has been shown to improve metabolic parameters, such as glucose tolerance, insulin sensitivity, and lipid profiles, in animal models of metabolic syndrome. It can also reduce oxidative stress and inflammation in adipose tissue, contributing to its beneficial effects on metabolism [26]. Clinical trials in humans have shown that melatonin supplementation can improve glycemic control and reduce blood pressure in individuals with metabolic syndrome [27].

6.4 Cancer

As mentioned earlier, melatonin exhibits oncostatic effects in various cancer cell lines and animal models. Clinical trials have shown that melatonin can improve the efficacy of chemotherapy and radiation therapy, reduce side effects, and improve overall survival in cancer patients [28]. However, the optimal dose and timing of melatonin administration in cancer treatment are still under investigation.

6.5 Other Applications

Melatonin has also been investigated for its potential therapeutic benefits in a variety of other conditions, including:
* Cardiovascular diseases: Melatonin can protect against myocardial infarction, stroke, and hypertension [29].
* Gastrointestinal disorders: Melatonin can protect against gastric ulcers, inflammatory bowel disease, and irritable bowel syndrome [30].
* Reproductive disorders: Melatonin can improve fertility in women with polycystic ovary syndrome (PCOS) and endometriosis [31].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Safety and Efficacy of Melatonin Supplementation

Melatonin is generally considered to be safe when taken at recommended doses. Common side effects are usually mild and include drowsiness, headache, dizziness, and nausea. However, some individuals may experience more severe side effects, such as anxiety, depression, and seizures, especially at high doses [32].

The efficacy of melatonin supplementation varies depending on the condition being treated and the individual’s response. While melatonin is effective for treating certain sleep disorders, such as delayed sleep phase syndrome and jet lag, its efficacy for treating chronic insomnia is less clear. Furthermore, the optimal dose and timing of melatonin administration can vary depending on the individual and the condition being treated.

It is important to note that melatonin supplements are regulated differently in different countries. In the United States, melatonin is classified as a dietary supplement and is not subject to the same rigorous testing and approval process as prescription drugs. As a result, the quality and purity of melatonin supplements can vary widely, and some products may contain inaccurate doses or contaminants. Therefore, it is important to purchase melatonin supplements from reputable manufacturers and to consult with a healthcare professional before taking melatonin, especially if you have any underlying health conditions or are taking other medications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Future Directions

Future research on melatonin should focus on:
* Investigating the mechanisms underlying melatonin’s pleiotropic effects: Further research is needed to fully understand the molecular mechanisms by which melatonin exerts its diverse physiological effects.
* Conducting large-scale clinical trials to determine the efficacy of melatonin in treating various diseases: More rigorous clinical trials are needed to evaluate the efficacy of melatonin in treating sleep disorders, neurodegenerative diseases, metabolic syndrome, and cancer.
* Developing novel melatonin analogs with improved bioavailability and efficacy: The short half-life of melatonin in circulation limits its therapeutic potential. Developing melatonin analogs with longer half-lives and improved receptor selectivity could enhance its efficacy.
* Investigating the role of melatonin in personalized medicine: Individual genetic makeup and circadian rhythms can influence melatonin production and response. Understanding these individual differences could allow for personalized melatonin therapy tailored to each patient’s needs.
* Determining the long-term safety of melatonin supplementation: While melatonin is generally considered to be safe, more research is needed to assess the long-term effects of melatonin supplementation, especially in children and adolescents.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Melatonin is a multifaceted molecule with diverse physiological roles extending far beyond sleep regulation. Its synthesis, regulation, and signaling pathways are complex and influenced by a variety of factors, including light exposure, aging, genetics, and diet. Melatonin’s antioxidant, anti-inflammatory, immunomodulatory, and oncostatic properties make it a potential therapeutic agent for a wide range of conditions, including sleep disorders, neurodegenerative diseases, metabolic syndrome, and cancer. While melatonin is generally considered to be safe, more research is needed to determine its long-term safety and efficacy. Future research should focus on elucidating the mechanisms underlying melatonin’s pleiotropic effects, conducting large-scale clinical trials, and developing novel melatonin analogs with improved bioavailability and efficacy. By continuing to explore the therapeutic potential of melatonin, we can unlock new strategies for preventing and treating a variety of diseases across the lifespan.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc. 1958;80(10):2587.

[2] Hardeland R. Melatonin: a pleiotropic, orchestrating regulator. J Pineal Res. 2017;62(2):e12399.

[3] Klein DC, Weller JL. Indole metabolism in the pineal gland: a circadian rhythm in N-acetyltransferase. Science. 1970;169(3942):1093-1095.

[4] Zawilska JB, Skene DJ, Arendt J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep. 2009;61(3):383-410.

[5] Ma X, Idle JR. Human cytochromes P450 and their genetic polymorphism. Drug Metab Rev. 2005;37(2):225-79.

[6] Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15(4):432-437.

[7] Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. A morphological and quantitative analysis of the human pineal gland from infancy to old age. J Pineal Res. 2003;35(1):11-8.

[8] Hardeland R. Melatonin and aging. Cell Mol Life Sci. 2018;75(18):3405-3422.

[9] Lyssenko V, Almgren P, Anevski D, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82-88.

[10] Meng X, Li Y, Li S, Zhou Y, Gan RY, Li HB. Dietary Sources and Bioactivities of Melatonin. Nutrients. 2017;9(4):367.

[11] Brivio R, Guarnieri C, Gambini O, et al. Interference of common drugs with the nocturnal melatonin surge: A systematic review. J Pineal Res. 2020;69(4):e12681.

[12] Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction and circadian disruption differentially regulate glucose tolerance, insulin sensitivity, and β-cell function in healthy humans. Sci Transl Med. 2012;4(129):129ra43.

[13] Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101-10.

[14] Hardeland R. New approaches to the management of insomnia: chronobiotics with emphasis on melatonin. Open Neuroendocrinol J. 2009;2:14-21.

[15] Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2):CD001520.

[16] Tan DX, Manchester LC, Esteban-Zubero E, Zhou Z, Ouslander JG, Reiter RJ. Melatonin as a potent and readily available antioxidant. J Pineal Res. 2015;59(1):1-21.

[17] Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52(4):365-75.

[18] Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine. 2005;27(2):189-200.

[19] Lissoni P, Barni S, Tancini G, et al. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in metastatic solid tumour patients treated with second-line chemotherapy. J Biol Regul Homeost Agents. 1999;13(2):67-9.

[20] Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the role of melatonin. Endocrine. 2005;27(2):179-88.

[21] Sainz RM, Mayo JC, Rodríguez C, Antolín I, Herrera F, Martín V, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003;60(7):1407-26.

[22] Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.

[23] Arendt J, Skene DJ, Middleton B, Lockley SW, Deacon S. Efficacy of melatonin in jet lag, shift work, and blindness. J Biol Rhythms. 1997;12(6):604-17.

[24] Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm disorder: an American Academy of Sleep Medicine review. Sleep. 2007;30(11):1484-501.

[25] Mayo JC, Sainz RM, Uria H, Antolin I, Rodriguez C, Herrera F, Reiter RJ. Melatonin and neuroprotection. Curr Neuropharmacol. 2005;3(3):201-22.

[26] Srinivasan V, Pandi-Perumal SR, Cardinali DP, Poeggeler B, Hardeland R. Melatonin in adipose tissue: the missing link between metabolic syndrome and the sleep disturbances associated with obesity? Obes Rev. 2012;13(7):630-44.

[27] Raygan F, Ostadmohammadi V, Bahmani F, Mohammadi H, Asemi Z. The effects of melatonin supplementation on glycemic control in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetol Metab Syndr. 2019;11:13.

[28] Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer. 2002;10(8):579-86.

[29] Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral S. Melatonin: a pleiotropic hormone with clinical relevance. Antioxid Redox Signal. 2016;24(13):678-701.

[30] Song GH, Lee SH, Kim MS, et al. Melatonin improves irritable bowel syndrome in children and adolescents through sleep regulation and serotonergic pathway modulation. J Pineal Res. 2016;60(4):367-75.

[31] Taghavi SA, Izadi A, Goodarzi N, Khadem-Ansari MH. Melatonin supplementation improves oocyte quality of infertile women undergoing in vitro fertilization: A randomized, double-blind, placebo-controlled trial. J Assist Reprod Genet. 2017;34(4):431-436.

[32] Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20(12):1151-68.